On this page
- Agomab Therapeutics NV IPO
- C&K Group Ltd IPO
- EIR Biopharma, Inc. IPO
- Exxel Pharma, INC. IPO
- Generate Biomedicines, Inc. IPO
- KINGTITAN TECHNOLOGY Ltd IPO
- Ping An Biomedical Co., Ltd. IPO
- Medikra Inc. IPO
- Once Upon a Farm, PBC IPO
- Softto Inc IPO
- SpyGlass Pharma, Inc. IPO
- Xinzi IPO
Agomab Therapeutics NV IPO
Agomab Therapeutics NV filed a Form F-1 registration statement for an initial public offering on 2026-01-16. It has amended it 1 time. It filed its final prospectus on 2026-02-06, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G, by Cormorant Asset Management, LP | 5.01% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Redmile Group, LLC | 5.6% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by SANOFI | 5.71% of the class | 5%+ stakes | Source |
| April 16, 2026 | Stake report, Schedule 13G, by Pontifax VI G.P. L.P. | 6.8% of the class | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 10% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13D, by LSP 7 Cooperatieve U.A. | 10.6% of the class | 5%+ stakes | Source |
Our ADSs have been approved for listing on the Nasdaq Global Select Market, or Nasdaq, under the symbol “AGMB.”From the 424B4 filed 2026-02-06
This is the initial public offering of 12,500,000 American Depositary Shares, or ADSs.From the 424B4 filed 2026-02-06
The initial public offering price per ADS is $16.00.From the 424B4 filed 2026-02-06
We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance clinical development of ontunisertib and AGMB-447 and to fund advancement of our preclinical candidates, one milestone payment pursuant to our acquisition agreement relating to Origo Biopharma, S.L., general and administrative expenses, and for working capital and other general corporate purposes.From the 424B4 filed 2026-02-06
C&K Group Ltd IPO
C&K Group Ltd filed a Form F-1 registration statement for an initial public offering on 2025-06-02. It has amended it 5 times. As of its latest filing, on 2026-02-13, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have reserved the symbol “CKJ” for purpose of listing our Class A Ordinary Shares on the Nasdaq Capital Market.From the F-1/A filed 2025-11-17
Our revenue was HKD66,839,374 and HKD70,814,654 (US$9,101,088) for the years ended September 30, 2024 and 2025, respectively.From the F-1 filed 2026-02-13
We recorded net income of HKD14,029,142 and HKD6,296,961 (US$809,285) for the years ended September 30, 2024 and 2025, respectively.From the F-1 filed 2026-02-13
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “ Securities Act ”), C&K Group Limited (the “ Company ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal, effective as of the date hereof, of the Company’s Registration Statement on Form F-1 (File No. 333-287713), together with all amendments and exhibits thereto (collectively, the “ Registration Statement ”).From the RW filed 2026-02-13
| Filed | What it is | Filing |
|---|---|---|
| 2025-06-02 | Registration statement filed (foreign issuer) | F-1 |
| 2025-08-25 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-09-05 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-09-19 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-10-28 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-11-17 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-02-13 | Request to withdraw a registration (Form F-1) | RW |
| 2026-02-13 | Registration statement filed (foreign issuer) | F-1 |
EIR Biopharma, Inc. IPO
EIR Biopharma, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-02-17. As of its latest filing, on 2026-02-17, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We intend to apply to list our common stock on the New York Stock Exchange, or NYSE, American under the symbol “____”.From the S-1 filed 2026-02-17
It is currently estimated that the initial public offering price will be between $4.00 and $5.00 per share.From the S-1 filed 2026-02-17
We intend to use the net proceeds from this offering to fund the preclinical and clinical development of EIR-1003, research activities, working capital and general corporate purposes.From the S-1 filed 2026-02-17
| Filed | What it is | Filing |
|---|---|---|
| 2026-02-17 | Registration statement filed | S-1 |
Exxel Pharma, INC. IPO
Exxel Pharma, INC. filed a Form S-1 registration statement for an initial public offering on 2025-09-19. It has amended it 2 times. As of its latest filing, on 2026-02-02, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 2, 2024 | Form D, private offering | $600K sold | Form D page | Source |
We intend to apply for listing of our common stock on the NYSE American under the symbol “EXXL”.From the S-1/A filed 2026-02-02
We intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, for clinical trials and product development, research and development, clinical manufacturing as well as for working capital and other general corporate purposes.From the S-1/A filed 2026-02-02
For the six months ended June 30, 2025, revenue decreased by approximately $175,000, or 100%, compared to the prior year period, due to the termination of licensing agreement at the end of the prior fiscal year.From the S-1/A filed 2025-10-14
For the years ended December 31, 2024 and 2023, we reported net losses of $409,171 and $430,098, respectively, and as of December 31, 2024 and December 31, 2023, we had accumulated deficits of $4,010,601 and $3,601,430, respectively.From the S-1/A filed 2026-02-02
Generate Biomedicines, Inc. IPO
Generate Biomedicines, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-02-04. It has amended it 2 times. It filed its final prospectus on 2026-02-27, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 5.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Flagship Pioneering, LLC | 48.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Nally Michael | 5.2% of the class | 5%+ stakes | Source |
Our common stock has been approved for listing on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “GENB.”From the 424B4 filed 2026-02-27
This is the initial public offering of shares of common stock of Generate Biomedicines, Inc. We are offering 25,000,000 shares of our common stock.From the 424B4 filed 2026-02-27
The initial public offering price per share is $16.00.From the 424B4 filed 2026-02-27
We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, primarily to (i) advance GB-0895 through the completion of our two Phase 3 trials in severe asthma, (ii) complete our ongoing Phase 1b clinical trial of GB-0895 for the treatment of COPD and to initiate the next phase of clinical development (pending results from our Phase 1b trial in COPD and regulatory alignment), (iii) fund platform and technology innovation and engineer multiple programs and product candidates through development candidate nomination and into IND-enabling activities and (iv) advance GB-4362 and GB-5267 through topline Phase 1…From the 424B4 filed 2026-02-27
We have incurred recurring losses since inception, including a net loss of $223.0 million and $181.4 million for the years ended December 31, 2025 and December 31, 2024, respectively.From the S-1/A filed 2026-02-23
KINGTITAN TECHNOLOGY Ltd IPO
KINGTITAN TECHNOLOGY Ltd has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2025-06-13. Amendments on record here: 3. As of its latest filing, on 2026-02-12, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have reserved the symbol “KTA” for purposes of listing our Class A Ordinary Shares on the Nasdaq Capital Market (“Nasdaq”) and have applied to list our Class A Ordinary Shares on Nasdaq.From the F-1/A filed 2026-02-12
We plan to use the net proceeds we receive from this offering for the following purposes:From the F-1/A filed 2026-02-12
For the six months ended September 30, 2025 and 2024, our revenue was $137,446 and $393,672, respectively.From the F-1/A filed 2026-02-12
For the same fiscal years, our net loss was $1,568,820 and $2,223,793, respectively.From the F-1/A filed 2026-02-12
Ping An Biomedical Co., Ltd. IPO
Ping An Biomedical Co., Ltd. filed a Form F-1 registration statement for an initial public offering on 2024-10-04. It has amended it 7 times. It filed its final prospectus on 2025-07-21, at a public offering price of $6.00 per share. Each fact below is quoted from the filing named with it.
Our Ordinary Shares are listed on the Nasdaq Stock Market under the symbol “PASW.” On February 12, 2026, the last reported sales price of our Ordinary Shares was $0.2185 per share.From the F-1 filed 2026-02-13
We are offering 2,500,000 Shares of MIHL, representing 12.2% of the Shares following the completion of this offering, assuming the underwriters do not exercise the over -allotment option.From the 424B4 filed 2025-07-21
The initial public offering price is $6.0 per Share.From the 424B4 filed 2025-07-21
We intend to use the net proceeds from this offering as follows:From the 424B4 filed 2025-07-21
Although we recorded net income of RMB237,704 (US$32,920) for the six months ended March 31, 2024, we cannot assure you that we will be able to continue to generate net income in the future.From the F-1/A filed 2024-11-04
Pursuant to Rule 477 under the Securities Act, the Company hereby requests that the Commission consent to the withdrawal of the Registration Statement, effective as of the date hereof.From the RW filed 2024-10-04
| Filed | What it is | Filing |
|---|---|---|
| 2024-10-04 | Request to withdraw a registration (Form F-1) | RW |
| 2024-10-04 | Registration statement filed (foreign issuer) | F-1 |
| 2024-10-23 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-11-04 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-01-24 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-03-17 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-03-25 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-04-14 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-06-26 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-07-21 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-02-13 | Registration statement filed (foreign issuer) | F-1 |
Medikra Inc. IPO
Medikra Inc. filed a Form F-1 registration statement for an initial public offering on 2026-01-20. It has amended it 1 time. As of its latest filing, on 2026-02-13, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have reserved the symbol “MDKR” for purposes of listing our Ordinary Shares on the Nasdaq Global Market (“Nasdaq”), and applied to list our Ordinary Shares on the Nasdaq.From the F-1/A filed 2026-02-13
We intend to use the net proceeds from this offering for the following purposes (i) clinical advancement of pipeline programs;From the F-1/A filed 2026-02-13
For the fiscal years ended December 31, 2024, and 2023, we generated total revenues of $26,176 and $68,381, respectively.From the F-1/A filed 2026-02-13
For the six months ended June 30, 2025, and 2024, the Group recorded a net loss of $628,823 and $131,662, respectively.From the F-1/A filed 2026-02-13
Once Upon a Farm, PBC IPO
Once Upon a Farm, PBC filed a Form S-1 registration statement for an initial public offering on 2025-09-29. It has amended it 2 times. It filed its final prospectus on 2026-02-09, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 3.7% of the class | 5%+ stakes | Source |
| October 19, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by WESTWOOD HOLDINGS GROUP INC | — | 5%+ stakes | Source |
| June 11, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.4% of the class | 5%+ stakes | Source |
| May 27, 2026 | Stake report, Schedule 13G, by WESTWOOD HOLDINGS GROUP INC | 5.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by CAVU Venture Partners II, LP | 17.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Foraker John M. | 6.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Garner Jennifer Anne | 7.1% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by S2G Investments, LLC | 14% of the class | 5%+ stakes | Source |
We have been approved to list our common stock on The New York Stock Exchange, or NYSE, under the symbol “OFRM.”From the 424B4 filed 2026-02-09
We are offering 7,631,537 shares of common stock, and the selling stockholders identified in this prospectus are offering 3,365,672 shares of common stock.From the 424B4 filed 2026-02-09
The initial public offering price of $18.00 per share is substantially higher than the net tangible book value per share of our outstanding common stock immediately after this offering.From the 424B4 filed 2026-02-09
We intend to use net proceeds received by us from this offering as follows:From the 424B4 filed 2026-02-09
We experienced net losses of $17.6 million and $23.8 million for the years ended December 31, 2023 and December 31, 2024, respectively, and net losses of $11.6 million and $39.8 million for the nine months ended September 30, 2024 and September 30, 2025, respectively.From the S-1/A filed 2026-01-28
Softto Inc IPO
Softto Inc filed a Form F-1 registration statement for an initial public offering on 2025-01-24. It has amended it 4 times. As of its latest filing, on 2026-02-13, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have reserved the trading symbol SFTO for listing on the NASDAQ.From the F-1/A filed 2025-03-07
We are offering on a firm commitment basis 3,000,000 ordinary shares.From the F-1/A filed 2025-03-07
Gross proceeds to us, net of underwriting discounts but before expenses (1) : $ Between $11,160,000 and $16,740,000, based on an offering price between $4.00 and $6.00 per share.From the F-1/A filed 2025-03-07
We intend to use the net proceeds of this offering:From the F-1/A filed 2025-09-12
During the six months ended June 30, 2025 and 2024, our revenues were approximately $3.1 million and $5.5 million, respectively, and net loss was approximately $1.3 million and $0.8 million, respectively.From the F-1/A filed 2026-02-13
During the six months ended June 30, 2025 and 2024, our revenues were approximately $3.1 million and $5.5 million, respectively, and net loss was approximately $1.3 million and $0.8 million, respectively.From the F-1/A filed 2026-02-13
| Filed | What it is | Filing |
|---|---|---|
| 2025-01-24 | Registration statement filed (foreign issuer) | F-1 |
| 2025-03-07 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-07-02 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-09-12 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-02-13 | Registration statement amended (foreign issuer) | F-1/A |
SpyGlass Pharma, Inc. IPO
SpyGlass Pharma, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-01-16. It has amended it 1 time. It filed its final prospectus on 2026-02-06, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13D, by RA Capital Management, L.P. | 24.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Srinivas Akkaraju | 6.3% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13D, by Gilde Healthcare Holding B.V. | 6.57% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13D, by New Enterprise Associates 17, L.P. | 22.2% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G, by SANDS FRANK M. | 7.8% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13D, by Vensana Capital I GP, LLC | 9.9% of the class | 5%+ stakes | Source |
| June 5, 2025 | Form D, private offering | $75M sold | Form D page | Source |
Our common stock has been approved for listing on the Nasdaq Global Select Market (Nasdaq) under the symbol “SGP.”From the 424B4 filed 2026-02-06
We are offering 9,375,000 shares of our common stock.From the 424B4 filed 2026-02-06
The initial public offering price is $16.00 per share of our common stock.From the 424B4 filed 2026-02-06
We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents and short-term investments, to advance our lead product candidate through the completion of two registrational Phase 3 clinical trials and, if approved, to fund the commercial launch of our lead product candidate, and the remainder for our other research and development activities, including the BIM-DRS and other preclinical activities, as well as for working capital and other general corporate purposes.From the 424B4 filed 2026-02-06
Our net losses were $29.2 million and $13.3 million for the years ended December 31, 2024 and 2023, respectively, and $27.3 million for the nine month period ended September 30, 2025.From the S-1/A filed 2026-01-29
Xinzi IPO
Xinzi filed a Form F-1 registration statement for an initial public offering on 2025-03-19. It has amended it 5 times. As of its latest filing, on 2026-02-10, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have applied to have our Ordinary Shares listed on the Nasdaq Capital Market under the symbol “XZ.” This offering is contingent on the listing of our Ordinary Shares on the Nasdaq Capital Market.From the F-1/A filed 2026-02-10
This is an initial public offering of 3,750,000 ordinary shares, par value US$0.0001 per share (the “Ordinary Shares”) on a firm commitment basis, of Xinzi, a Cayman Islands exempted company.From the F-1/A filed 2026-02-10
We expect the initial public offering price of our Ordinary Shares will be between $4.00 and $6.00 per Ordinary Share.From the F-1/A filed 2026-02-10
In the six months ended June 30, 2025 and 2024, our revenue was US$8,836,351 and US$12,608,308, respectively.From the F-1/A filed 2026-02-10
We had a net income of US$8,568 for the six months ended June 30, 2025 and net loss of $700,723 for the six months ended June 30, 2024.From the F-1/A filed 2026-02-10
| Filed | What it is | Filing |
|---|---|---|
| 2025-03-19 | Registration statement filed (foreign issuer) | F-1 |
| 2025-07-01 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-08-08 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-08-29 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-11-14 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-02-10 | Registration statement amended (foreign issuer) | F-1/A |
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.